Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects of combining an experimental drug called fianlimab REGN3767 with cemiplimab, compared to cemiplimab with a placebo, in people with recurrent or metastatic head and neck squamous cell carcinoma HNSCC that has not been previously treated. The study focuses on patients whose cancer is positive for PD-L1 expression and aims to understand side effects, drug levels in the blood, and immune responses to the treatments. Participants are divided into two groups based on HPV status one with HPV-positive HNSCC and the other with HPV-negative HNSCC. Each group is randomly assigned to receive either the combination of fianlimab and cemiplimab or cemiplimab with placebo. Both treatments are given as fixed-dose combinations according to the study protocol. During the study, participants will be monitored for up to about 58 months, including assessments of overall response rate, disease control, progression-free survival, and duration of response. Researchers will also track various types of adverse events and measure drug concentrations and antibody responses in the blood. Safety and treatment effects will be evaluated throughout and up to 90 days after the last treatment dose.
Actively Recruiting
Researchers are evaluating the effects of lowering blood phosphate levels in adults with end-stage kidney disease ESKD who are receiving dialysis. This trial compares intensive lowering of serum phosphate towards the normal level 1.50 mmolL with a more liberal target 2.0 to 2.5 mmolL to see if it reduces death or major cardiovascular events, and improves physical health and quality of life. The study is a large, international, randomized controlled trial sponsored by The University of Queensland. Participants will be randomly assigned to one of two groups one targeting a liberal serum phosphate level where phosphate-lowering medications are only prescribed if levels exceed 2.5 mmolL, and the other aiming for an intensive target with medications used to lower phosphate to normal levels. The choice and dose of phosphate binders will be decided by the treating physician and participant. The treatment period is expected to last up to five years. During the study, participants will be monitored for cardiovascular events, death, physical health, fatigue, quality of life, and patient satisfaction. Assessments include tracking the time to cardiovascular death or major cardiovascular events, all-cause death, and quality of life using the EQ5D-5L measure. Data will be collected throughout the treatment period, with safety and effectiveness evaluated over five years.